EVA is registered trademark of Stern Stewart.
Economic value added or economic profit is the difference between revenues and costs,where costs include not only expenses, but also cost of capital.
Economic Profit
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cost of capital. See details »
3 Invested capital. See details »
4 2025 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= 28,330 – 8.96% × 138,153 = 15,956
The financial trajectory from 2021 to 2025 is characterized by significant volatility in value creation, marked by a severe contraction in economic profit through 2023 followed by a robust recovery. While the cost of capital remained virtually stagnant, the fluctuations in net operating profit after taxes (NOPAT) and invested capital drove the overall economic performance.
- Net Operating Profit After Taxes (NOPAT)
- A pronounced downward trend is observed from 2021 to 2023, with NOPAT falling from 18,861 million US$ to a period low of 8,905 million US$. This represents a decline of over 50% in operating profitability within two years. However, a strong reversal occurred thereafter, with profits increasing to 11,461 million US$ in 2024 and surging to 28,330 million US$ by December 28, 2025, indicating a substantial recovery in operational efficiency and earnings power.
- Invested Capital and Cost of Capital
- The cost of capital remained exceptionally stable throughout the analyzed period, fluctuating minimally between 8.87% and 8.96%. In contrast, invested capital exhibited more variance, increasing from 98,066 million US$ in 2021 to a peak of 138,153 million US$ in 2025. A temporary reduction in invested capital was noted in 2023, falling to 99,118 million US$ after a peak in 2022, suggesting a period of capital reallocation or divestiture.
- Economic Profit and Value Creation
- Economic profit experienced a precipitous decline, starting at 10,152 million US$ in 2021 and nearly reaching a break-even point of 27 million US$ by December 31, 2023. This indicates that by 2023, NOPAT barely exceeded the required return on invested capital, resulting in negligible value creation for shareholders. The subsequent period showed a sharp recovery, with economic profit rising to 2,001 million US$ in 2024 and reaching a period high of 15,956 million US$ in 2025. This final peak suggests that the increase in NOPAT significantly outpaced the growth in the cost of capital charges associated with the expanded invested capital base.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Net Operating Profit after Taxes (NOPAT)
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Elimination of deferred tax expense. See details »
2 Addition of increase (decrease) in allowances for doubtful accounts.
3 Addition of increase (decrease) in equity equivalents to net earnings.
4 2025 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= 1,400 × 3.54% = 50
5 2025 Calculation
Tax benefit of interest expense, net of portion capitalized = Adjusted interest expense, net of portion capitalized × Statutory income tax rate
= 1,021 × 21.00% = 214
6 Addition of after taxes interest expense to net earnings.
7 2025 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= 1,056 × 21.00% = 222
8 Elimination of after taxes investment income.
9 Elimination of discontinued operations.
The reported Net Operating Profit After Taxes (NOPAT) demonstrates considerable fluctuation over the five-year period. While net earnings exhibit volatility, NOPAT presents a distinct pattern of decline followed by recovery.
- Overall Trend
- NOPAT decreased from US$18,861 million in 2021 to US$8,905 million in 2023, representing a substantial reduction. However, a significant recovery is then observed, with NOPAT increasing to US$11,461 million in 2024 and further to US$28,330 million in 2025. This indicates a period of operational challenges followed by improved performance.
- Year-over-Year Changes
- A decrease in NOPAT of approximately 14.8% is noted between 2021 and 2022. The most significant decline occurred between 2022 and 2023, with a decrease of roughly 44.3%. Conversely, the largest increase in NOPAT was observed between 2024 and 2025, showing a growth of approximately 147.2%. The increase from 2023 to 2024 was approximately 28.7%.
- Relationship to Net Earnings
- While both NOPAT and net earnings fluctuate, they do not move in perfect correlation. For example, net earnings decreased substantially from 2021 to 2022, while the NOPAT decrease was less pronounced. In 2023, net earnings increased significantly, but NOPAT remained comparatively low. This divergence suggests factors beyond core operational profitability are influencing net earnings, such as non-operating items or accounting adjustments.
The substantial recovery in NOPAT during 2024 and 2025 suggests successful implementation of operational improvements, cost controls, or favorable market conditions. Further investigation into the drivers behind these changes is warranted to understand the sustainability of the recent performance.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cash Operating Taxes
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
The provision for taxes on income and cash operating taxes exhibited fluctuating behavior over the observed five-year period. A review of the figures reveals distinct patterns in both metrics, suggesting potential influences from changes in accounting practices, tax regulations, or operational performance.
- Provision for Taxes on Income
- The provision for taxes on income increased significantly from US$1,898 million in 2021 to US$3,784 million in 2022. This was followed by a substantial decrease to US$1,736 million in 2023. A moderate increase occurred in 2024, reaching US$2,621 million, before a considerable rise to US$5,777 million in 2025. This pattern indicates considerable volatility, potentially linked to one-time gains or losses, changes in tax rates, or alterations in deferred tax assets and liabilities.
- Cash Operating Taxes
- Cash operating taxes demonstrated an upward trend from US$4,010 million in 2021 to US$5,411 million in 2022, mirroring the increase observed in the provision for taxes on income. A further increase to US$5,700 million occurred in 2023, representing the highest value in the observed period. Subsequently, cash operating taxes decreased to US$4,692 million in 2024 and continued to decline to US$4,232 million in 2025. This suggests a potential decoupling from the provision for taxes on income in the later years, possibly due to timing differences in tax payments or changes in tax credits utilized.
The divergence between the provision for taxes on income and cash operating taxes is particularly noticeable in 2024 and 2025. While the provision for taxes on income increased substantially in 2025, cash operating taxes decreased. This discrepancy warrants further investigation to determine the underlying causes, such as changes in the utilization of net operating loss carryforwards, installment payments, or other tax planning strategies. The fluctuations observed in both metrics suggest a dynamic tax environment and the potential for significant impacts on future financial performance.
- Relationship between Metrics
- In 2021, 2022, and 2023, cash operating taxes were consistently higher than the provision for taxes on income. However, this relationship shifted in 2024 and 2025, with the provision for taxes on income exceeding cash operating taxes. This reversal could indicate a build-up of deferred tax liabilities or a change in the timing of tax payments relative to reported income.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Invested Capital
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Addition of capitalized operating leases.
2 Elimination of deferred taxes from assets and liabilities. See details »
3 Addition of allowance for doubtful accounts receivable.
4 Addition of equity equivalents to shareholders’ equity.
5 Removal of accumulated other comprehensive income.
6 Subtraction of construction in progress.
7 Subtraction of current marketable securities.
The invested capital of the company exhibited a fluctuating pattern over the five-year period. Total reported debt & leases and shareholders’ equity, the components of invested capital, both demonstrated variability during this time. An initial increase in invested capital was followed by a period of decline and subsequent growth.
- Invested Capital Trend
- Invested capital increased from US$98,066 million in 2021 to US$113,818 million in 2022, representing a substantial rise. This was followed by a decrease to US$99,118 million in 2023. A further increase was observed in 2024, reaching US$106,513 million, before a significant jump to US$138,153 million in 2025. This suggests a period of expansion followed by consolidation and then renewed growth.
- Debt & Leases
- Total reported debt & leases increased from US$34,751 million in 2021 to US$40,959 million in 2022. A notable decrease occurred in 2023, with debt falling to US$30,432 million. Debt levels then rose again in 2024 to US$37,834 million, and continued to increase substantially in 2025, reaching US$49,333 million. This indicates a dynamic debt management strategy, potentially influenced by investment opportunities or financing needs.
- Shareholders’ Equity
- Shareholders’ equity showed a modest increase from US$74,023 million in 2021 to US$76,804 million in 2022. A decline was then recorded in 2023, with equity decreasing to US$68,774 million. Equity recovered somewhat in 2024, reaching US$71,490 million, and experienced a more significant increase in 2025, rising to US$81,544 million. These fluctuations may be attributable to profitability, dividend payouts, and share repurchase activities.
The substantial increase in invested capital in 2025 appears to be driven by a combination of increased debt and shareholders’ equity. The relative contributions of each component to the overall invested capital change over time, suggesting shifts in the company’s capital structure.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Cost of Capital
Johnson & Johnson, cost of capital calculations
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 580,448) | 580,448) | ÷ | 628,081) | = | 0.92 | 0.92 | × | 9.46% | = | 8.74% | ||
| Borrowings3 | 46,233) | 46,233) | ÷ | 628,081) | = | 0.07 | 0.07 | × | 3.54% × (1 – 21.00%) | = | 0.21% | ||
| Operating lease liability4 | 1,400) | 1,400) | ÷ | 628,081) | = | 0.00 | 0.00 | × | 3.54% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 628,081) | 1.00 | 8.96% | ||||||||||
Based on: 10-K (reporting date: 2025-12-28).
1 US$ in millions
2 Equity. See details »
3 Borrowings. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 378,598) | 378,598) | ÷ | 414,432) | = | 0.91 | 0.91 | × | 9.46% | = | 8.64% | ||
| Borrowings3 | 34,634) | 34,634) | ÷ | 414,432) | = | 0.08 | 0.08 | × | 3.48% × (1 – 21.00%) | = | 0.23% | ||
| Operating lease liability4 | 1,200) | 1,200) | ÷ | 414,432) | = | 0.00 | 0.00 | × | 3.48% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 414,432) | 1.00 | 8.88% | ||||||||||
Based on: 10-K (reporting date: 2024-12-29).
1 US$ in millions
2 Equity. See details »
3 Borrowings. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 377,093) | 377,093) | ÷ | 406,525) | = | 0.93 | 0.93 | × | 9.46% | = | 8.78% | ||
| Borrowings3 | 28,332) | 28,332) | ÷ | 406,525) | = | 0.07 | 0.07 | × | 3.14% × (1 – 21.00%) | = | 0.17% | ||
| Operating lease liability4 | 1,100) | 1,100) | ÷ | 406,525) | = | 0.00 | 0.00 | × | 3.14% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 406,525) | 1.00 | 8.96% | ||||||||||
Based on: 10-K (reporting date: 2023-12-31).
1 US$ in millions
2 Equity. See details »
3 Borrowings. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 412,102) | 412,102) | ÷ | 451,461) | = | 0.91 | 0.91 | × | 9.46% | = | 8.64% | ||
| Borrowings3 | 38,059) | 38,059) | ÷ | 451,461) | = | 0.08 | 0.08 | × | 3.38% × (1 – 21.00%) | = | 0.23% | ||
| Operating lease liability4 | 1,300) | 1,300) | ÷ | 451,461) | = | 0.00 | 0.00 | × | 3.38% × (1 – 21.00%) | = | 0.01% | ||
| Total: | 451,461) | 1.00 | 8.87% | ||||||||||
Based on: 10-K (reporting date: 2022-12-31).
1 US$ in millions
2 Equity. See details »
3 Borrowings. See details »
4 Operating lease liability. See details »
| Capital (fair value)1 | Weights | Cost of capital | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity2 | 436,958) | 436,958) | ÷ | 474,909) | = | 0.92 | 0.92 | × | 9.46% | = | 8.71% | ||
| Borrowings3 | 36,951) | 36,951) | ÷ | 474,909) | = | 0.08 | 0.08 | × | 2.76% × (1 – 21.00%) | = | 0.17% | ||
| Operating lease liability4 | 1,000) | 1,000) | ÷ | 474,909) | = | 0.00 | 0.00 | × | 2.76% × (1 – 21.00%) | = | 0.00% | ||
| Total: | 474,909) | 1.00 | 8.88% | ||||||||||
Based on: 10-K (reporting date: 2021-12-31).
1 US$ in millions
2 Equity. See details »
3 Borrowings. See details »
4 Operating lease liability. See details »
Economic Spread Ratio
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | 15,956) | 2,001) | 27) | 6,020) | 10,152) | |
| Invested capital2 | 138,153) | 106,513) | 99,118) | 113,818) | 98,066) | |
| Performance Ratio | ||||||
| Economic spread ratio3 | 11.55% | 1.88% | 0.03% | 5.29% | 10.35% | |
| Benchmarks | ||||||
| Economic Spread Ratio, Competitors4 | ||||||
| AbbVie Inc. | 0.72% | -2.22% | -3.93% | 5.49% | 4.87% | |
| Amgen Inc. | 6.25% | -0.54% | 2.28% | 6.80% | 6.80% | |
| Bristol-Myers Squibb Co. | 5.66% | -22.01% | 1.55% | -1.21% | 1.09% | |
| Danaher Corp. | -10.71% | -10.87% | -11.64% | -6.63% | -5.80% | |
| Eli Lilly & Co. | 30.14% | 14.49% | 1.42% | 8.52% | 10.19% | |
| Gilead Sciences Inc. | 12.61% | -10.47% | 2.85% | -0.27% | 6.76% | |
| Merck & Co. Inc. | 10.49% | 13.36% | -8.94% | 11.24% | 11.41% | |
| Pfizer Inc. | -3.69% | -3.37% | -9.48% | 17.97% | 11.14% | |
| Regeneron Pharmaceuticals Inc. | 13.82% | 16.64% | 13.44% | 18.80% | 62.56% | |
| Thermo Fisher Scientific Inc. | -7.45% | -8.25% | -8.72% | -6.97% | -4.95% | |
| Vertex Pharmaceuticals Inc. | 20.79% | -22.86% | 11.09% | 13.84% | 15.05% | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 Invested capital. See details »
3 2025 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × 15,956 ÷ 138,153 = 11.55%
4 Click competitor name to see calculations.
The analysis of economic value creation reveals a period of significant volatility followed by a substantial recovery in profitability relative to the cost of capital. Between 2021 and 2025, a distinct V-shaped trajectory is observed in both absolute economic profit and the efficiency of capital utilization.
- Economic Spread Ratio
- A sharp contraction occurred from 10.35% in 2021 to a near-zero level of 0.03% by 2023, indicating that the return on invested capital almost converged with the cost of capital. This trough was followed by a gradual recovery to 1.88% in 2024 and a significant expansion to a five-year peak of 11.55% by 2025, signaling a strong restoration of value creation efficiency.
- Economic Profit
- Absolute economic profit experienced a severe decline, falling from 10,152 million USD in 2021 to a marginal 27 million USD in 2023. This represents a near-total erosion of economic value added over a two-year window. A rapid acceleration followed, culminating in a peak of 15,956 million USD in 2025, which significantly exceeds the levels observed at the start of the analyzed period.
- Invested Capital Dynamics
- Invested capital fluctuated between 98,066 million USD and 113,818 million USD from 2021 through 2024. A notable expansion occurred in 2025, with invested capital rising to 138,153 million USD. The simultaneous increase in both invested capital and the economic spread ratio in 2025 indicates that the additional capital deployed was highly accretive, contributing to a substantial increase in overall economic value.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Economic Profit Margin
| Dec 28, 2025 | Dec 29, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Economic profit1 | 15,956) | 2,001) | 27) | 6,020) | 10,152) | |
| Sales to customers | 94,193) | 88,821) | 85,159) | 94,943) | 93,775) | |
| Performance Ratio | ||||||
| Economic profit margin2 | 16.94% | 2.25% | 0.03% | 6.34% | 10.83% | |
| Benchmarks | ||||||
| Economic Profit Margin, Competitors3 | ||||||
| AbbVie Inc. | 0.72% | -2.73% | -4.94% | 7.77% | 8.31% | |
| Amgen Inc. | 10.42% | -1.06% | 5.93% | 10.90% | 11.26% | |
| Bristol-Myers Squibb Co. | 6.96% | -28.55% | 2.33% | -1.87% | 1.88% | |
| Danaher Corp. | -32.81% | -33.56% | -38.22% | -16.48% | -14.50% | |
| Eli Lilly & Co. | 22.94% | 11.51% | 1.22% | 7.25% | 9.40% | |
| Gilead Sciences Inc. | 18.67% | -16.23% | 4.86% | -0.46% | 11.95% | |
| Merck & Co. Inc. | 15.81% | 16.54% | -10.41% | 14.02% | 16.57% | |
| Pfizer Inc. | -8.24% | -7.17% | -24.66% | 19.67% | 11.89% | |
| Regeneron Pharmaceuticals Inc. | 12.76% | 14.59% | 12.26% | 18.93% | 42.30% | |
| Thermo Fisher Scientific Inc. | -15.75% | -15.79% | -17.42% | -12.85% | -10.07% | |
| Vertex Pharmaceuticals Inc. | 18.34% | -18.76% | 14.88% | 20.42% | 18.65% | |
Based on: 10-K (reporting date: 2025-12-28), 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Economic profit. See details »
2 2025 Calculation
Economic profit margin = 100 × Economic profit ÷ Sales to customers
= 100 × 15,956 ÷ 94,193 = 16.94%
3 Click competitor name to see calculations.
The financial performance between 2021 and 2025 is characterized by significant volatility in economic value creation, culminating in a substantial recovery and a period of peak profitability by the end of the analyzed timeframe.
- Economic Profit Margin Analysis
- A sharp contraction is observed from 2021 to 2023, with the margin falling from 10.83% to a near-zero value of 0.03%. This trend indicates a period where the company barely generated returns above its cost of capital. A strong recovery followed, with the margin increasing to 2.25% in 2024 and reaching a five-year peak of 16.94% in 2025.
- Economic Profit Fluctuations
- Economic profit experienced a severe decline, dropping from 10,152 million US dollars in 2021 to a low of 27 million US dollars in 2023. The subsequent turnaround resulted in a profit of 2,001 million US dollars in 2024 and a significant surge to 15,956 million US dollars in 2025, marking the highest level of absolute economic value added within the period.
- Revenue and Efficiency Correlation
- Sales to customers showed a degree of stability, despite a notable dip to 85,159 million US dollars in 2023. The fact that the economic profit margin collapsed more severely than the sales decline suggests that factors beyond revenue—such as increased capital charges or operational costs—contributed to the 2023 downturn. The 2025 results show that while sales returned to levels similar to 2021 and 2022, the economic profit margin expanded far beyond previous levels, indicating a substantial improvement in the efficiency of capital utilization.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?